Impact of new technologies for cellular screening along the drug value chain

Drug Discovery Today

Volumn 15, Issue 9-10, 2010, Pages 384-390

  Möller, Clemens ^a   Slack, Mark ^a  

^a EVOTEC AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; ION CHANNEL; POTASSIUM CHANNEL HERG; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; VOLTAGE GATED SODIUM CHANNEL;

ATOMIC FORCE MICROSCOPY; DRUG BINDING SITE; DRUG RESEARCH; DRUG SCREENING; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART MUSCLE CELL; HIGH THROUGHPUT SCREENING; HUMAN; IMPEDANCE; LAB ON A CHIP; MICROELECTRODE; NEURAL STEM CELL; NONHUMAN; PATCH CLAMP; PLURIPOTENT STEM CELL; REFRACTION INDEX; REVIEW;

ANIMALS; BIOLOGICAL ASSAY; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ION CHANNELS; MICROSCOPY, ATOMIC FORCE; PATCH-CLAMP TECHNIQUES; RECEPTORS, CELL SURFACE; STEM CELLS;

EID: 77952546520     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.02.010     Document Type: Review

References (79)

1. David E., et al. Pharmaceutical R&D: the road to positive returns. Nat. Rev. Drug Discov. 2009, 8:609-610.
2. Prous J.R., Khurdayan V.K. The story so far in R&D. Drug News Perspect. 2007, 20:7-15.
3. Zambrowicz B.P., Sands A.T. Knockouts model the 100 best-selling drugs - will they model the next 100?. Nat. Rev. Drug Discov. 2003, 2:38-51.
4. Geffner L.F., et al. Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies. Cell Transplant. 2008, 17:1277-1293.
5. Krause K., et al. Percutaneous intramyocardial stem cell injection in patients with acute myocardial infarction: first-in-man study. Heart 2009, 95:1145-1152.
6. Borowiak M., et al. Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell 2009, 4:348-358.
7. Desbordes S.C., et al. High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. Cell Stem Cell 2008, 2:602-612.
8. Liu Y., et al. Identification of small-molecule modulators of mouse SVZ progenitor cell proliferation and differentiation through high-throughput screening. J. Biomol. Screen. 2009, 14:319-329.
9. Chen S., et al. A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nat. Chem. Biol. 2009, 5:258-265.
10. Takahashi K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
11. Chin M.H., et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 2009, 5:111-123.
12. Dimos J.T., et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321:1218-1221.
13. Park I.H., et al. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
14. Ebert A.D., et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457:277-280.
15. Miura K., et al. Variation in the safety of induced pluripotent stem cell lines. Nat. Biotechnol. 2009, 27:743-745.
16. Kawamura T., et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009, 460:1140-1144.
17. Marion R.M., et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009, 460:1149-1153.
18. Bertelsen M. Multiplex analysis of inflammatory signaling pathways using a high-content imaging system. Methods Enzymol. 2006, 414:348-363.
19. Durr O., et al. Robust hit identification by quality assurance and multivariate data analysis of a high-content, cell-based assay. J. Biomol. Screen. 2007, 12:1042-1049.
20. Young D.W., et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat. Chem. Biol. 2008, 4:59-68.
21. Muller F.J., et al. Regulatory networks define phenotypic classes of human stem cell lines. Nature 2008, 455:401-405.
22. Abraham V.C., et al. Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. J. Biomol. Screen. 2008, 13:527-537.
23. Haasen D., et al. Pharmacological profiling of chemokine receptor-directed compounds using high-content screening. J. Biomol. Screen. 2008, 13:40-53.
24. Antczak C., et al. Live-cell imaging of caspase activation for high-content screening. J. Biomol. Screen. 2009, 14:956-969.
25. Wolff M., et al. Activation and translocation of glucokinase in rat primary hepatocytes monitored by high content image analysis. J. Biomol. Screen. 2008, 13:837-846.
26. Vogt A., et al. The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J. Biol. Chem. 2005, 280:19078-19086.
27. Kwon Y.J., et al. High-content classification of nucleocytoplasmic import or export inhibitors. J. Biomol. Screen. 2007, 12:621-627.
28. Haasen D., et al. G protein-coupled receptor internalization assays in the high-content screening format. Methods Enzymol. 2006, 414:121-139.
29. Heilker R., et al. G-protein-coupled receptor-focused drug discovery using a target class platform approach. Drug Discov. Today 2009, 14:231-240.
30. O'Brien P.J., et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80:580-604.
31. Ainscow E.K., et al. Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures. Expert Opin. Drug Saf. 2008, 7:351-365.
32. Radio N.M., et al. Assessment of chemical effects on neurite outgrowth in PC12 cells using high content screening. Toxicol. Sci. 2008, 105:106-118.
33. Evensen L., et al. Mural cell associated VEGF is required for organotypic vessel formation. PLoS One 2009, 4:e5798.
34. Hu M., et al. High content screen microscopy analysis of A beta 1-42-induced neurite outgrowth reduction in rat primary cortical neurons: neuroprotective effects of alpha 7 neuronal nicotinic acetylcholine receptor ligands. Brain Res. 2007, 1151:227-235.
35. Shiau A.K., et al. Back to basics: label-free technologies for small molecule screening. Comb. Chem. High Throughput Screen. 2008, 11:231-237.
36. Xi B., et al. The application of cell-based label-free technology in drug discovery. Biotechnol. J. 2008, 3:484-495.
37. Jahnke H.G., et al. An impedimetric microelectrode-based array sensor for label-free detection of tau hyperphosphorylation in human cells. Lab Chip 2009, 9:1422-1428.
38. Lee P.H., et al. Evaluation of dynamic mass redistribution technology for pharmacological studies of recombinant and endogenously expressed g protein-coupled receptors. Assay Drug Dev. Technol. 2008, 6:83-94.
39. Peters M.F., et al. Evaluation of cellular dielectric spectroscopy, a whole-cell, label-free technology for drug discovery on Gi-coupled GPCRs. J. Biomol. Screen. 2007, 12:312-319.
40. Fang Y., et al. Characteristics of dynamic mass redistribution of epidermal growth factor receptor signaling in living cells measured with label-free optical biosensors. Anal. Chem. 2005, 77:5720-5725.
41. Dunlop J., et al. High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat. Rev. Drug Discov. 2008, 7:358-368.
42. Hamill O.P., et al. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981, 391:85-100.
43. Neher E., Sakmann B. Single-channel currents recorded from membrane of denervated frog muscle fibres. Nature 1976, 260:799-802.
44. Finkel A., et al. Population patch clamp improves data consistency and success rates in the measurement of ionic currents. J. Biomol. Screen. 2006, 11:488-496.
45. Dale T.J., et al. Population patch clamp electrophysiology: a breakthrough technology for ion channel screening. Mol. Biosyst. 2007, 3:714-722.
46. Friis S., et al. Characterization of compounds on nicotinic acetylcholine receptor alpha7 channels using higher throughput electrophysiology. J. Neurosci. Methods 2009, 177:142-148.
47. Dabrowski M. Global ion channel initiative. Ion Channel Retreat June 29-July 1, 2009 2009, See also the Cellectricon web site.
48. Dahan E., et al. Rapid fluidic exchange microsystem for recording of fast ion channel kinetics in Xenopus oocytes. Lab Chip 2008, 8:1809-1818.
49. Stett A., et al. Biological application of microelectrode arrays in drug discovery and basic research. Anal. Bioanal. Chem. 2003, 377:486-495.
50. Castle N., et al. Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms. Comb. Chem. High Throughput Screen. 2009, 12:107-122.
51. Amir R., et al. The role of sodium channels in chronic inflammatory and neuropathic pain. J. Pain 2006, 7:S1-S29.
52. Dib-Hajj S.D., et al. Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment. Brain Res. Rev. 2009, 60:65-83.
53. Schmalhofer W.A., et al. ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. Mol. Pharmacol. 2008, 74:1476-1484.
54. Sanguinetti M.C., Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440:463-469.
55. Guo L., Guthrie H. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J. Pharmacol. Toxicol. Methods 2005, 52:123-135.
56. Kutchinsky J., et al. Characterization of potassium channel modulators with QPatch automated patch-clamp technology: system characteristics and performance. Assay Drug Dev. Technol. 2003, 1:685-693.
57. Pugsley M.K. Methodology used in safety pharmacology: appraisal of the state-of-the-art, the regulatory issues and new directions. J. Pharmacol. Toxicol. Methods 2005, 52:1-5.
58. Sorota S., et al. Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen. Assay Drug Dev. Technol. 2005, 3:47-57.
59. Tao H., et al. Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev. Technol. 2004, 2:497-506.
60. Kettenhofen R., Bohlen H. Preclinical assessment of cardiac toxicity. Drug Discov. Today 2008, 13:702-707.
61. Steel D., et al. Cardiomyocytes derived from human embryonic stem cells - characteristics and utility for drug discovery. Curr. Opin. Drug Discov. Devel. 2009, 12:133-140.
62. Bin Z., et al. Efficient cardiomyocyte differentiation of embryonic stem cells by bone morphogenetic protein-2 combined with visceral endoderm-like cells. Cell Biol. Int. 2006, 30:769-776.
63. Igelmund P., et al. Action potential propagation failures in long-term recordings from embryonic stem cell-derived cardiomyocytes in tissue culture. Pflugers Arch. 1999, 437:669-679.
64. Passier R., Mummery C. Cardiomyocyte differentiation from embryonic and adult stem cells. Curr. Opin. Biotechnol. 2005, 16:498-502.
65. Shang L.L., et al. Analysis of arrhythmic potential of embryonic stem cell-derived cardiomyocytes. Methods Mol. Biol. 2006, 330:221-231.
66. van Ginneken A.C., Fijnvandraat A.C. Electrophysiological properties of embryonic stem cells during differentiation into cardiomyocyte-like cell types. Methods Mol. Biol. 2007, 403:211-217.
67. Binnig G., et al. Atomic force microscope. Phys. Rev. Lett. 1986, 56:930-933.
68. Drake B., et al. Imaging crystals, polymers, and processes in water with the atomic force microscope. Science 1989, 243:1586-1589.
69. Muller D.J., et al. Imaging purple membranes in aqueous solutions at sub-nanometer resolution by atomic force microscopy. Biophys. J. 1995, 68:1681-1686.
70. Butt H.J. Measuring local surface charge densities in electrolyte solutions with a scanning force microscope. Biophys. J. 1992, 63:578-582.
71. Moller C., et al. Reversible loss of crystallinity on photobleaching purple membrane in the presence of hydroxylamine. J. Mol. Biol. 2000, 301:869-879.
72. Muller D.J., et al. Stability of bacteriorhodopsin alpha-helices and loops analyzed by single-molecule force spectroscopy. Biophys. J. 2002, 83:3578-3588.
73. Oesterhelt F., et al. Unfolding pathways of individual bacteriorhodopsins. Science 2000, 288:143-146.
74. Helenius J., et al. Single-cell force spectroscopy. J. Cell Sci. 2008, 121:1785-1791.
75. Benoit M., et al. Discrete interactions in cell adhesion measured by single-molecule force spectroscopy. Nat. Cell Biol. 2000, 2:313-317.
76. Aigner T., et al. Nanomedicine: AFM tackles osteoarthritis. Nat. Nanotechnol. 2009, 4:144-145.
77. Stolz M., et al. Early detection of aging cartilage and osteoarthritis in mice and patient samples using atomic force microscopy. Nat. Nanotechnol. 2009, 4:186-192.
78. Collier R. Drug development cost estimates hard to swallow. CMAJ 2009, 180:279-280.
79. Weiss D., et al. The 'big pharma' dilemma: develop new drugs or promote existing ones?. Nat. Rev. Drug Discov. 2009, 8:533-534.